Table 4.
Distribution frequency of the clinical status and MMP-11 rs131451 genotype frequencies in 479 CRC patients with different genders.
| Variable | All (N = 479) | Male (N = 282) | Female (N = 197) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| TT (N = 161) |
TC + CC (N = 318) |
p Value | TT (N = 96) |
TC + CC (N = 186) |
p value | TT (N = 65) |
TC + CC (N = 132) |
p Value | |
| Stages | |||||||||
| I + II | 80 (49.7%) | 149 (46.9%) | p = 0.317 | 51 (53.1%) | 94 (50.5%) | p = 0.812 | 29 (44.6%) | 55 (41.7%) | p = 0.134 |
| III + IV | 81 (50.3%) | 169 (53.1%) | 45 (46.9%) | 92 (49.5%) | 36 (55.4%) | 77 (58.3%) | |||
| Tumor T status | |||||||||
| T1 + T2 | 47 (29.2%) | 69 (21.7%) | p = 0.216 | 34 (35.4%) | 43 (23.1%) | p = 0.028 a | 13 (20.0%) | 26 (19.7%) | p = 0.999 |
| T3 + T4 | 114 (70.8%) | 249 (78.3%) | 62 (64.6%) | 143 (76.9%) | 52 (80.0%) | 106 (80.3%) | |||
| Lymph node status | |||||||||
| Negative | 81 (50.3%) | 158 (49.7%) | p = 0.238 | 52 (54.2%) | 99 (53.2%) | p = 0.545 | 29 (44.6%) | 59 (44.7%) | p = 0.172 |
| Positive | 80 (49.7%) | 160 (50.3%) | 44 (45.8%) | 87 (46.8%) | 36 (55.4%) | 73 (55.3%) | |||
| Metastasis | |||||||||
| Negative | 135 (83.9%) | 267 (84.0%) | p = 0.380 | 84 (87.5%) | 157 (84.4%) | p = 0.663 | 51 (78.5%) | 110 (83.3%) | p = 0.152 |
| Positive | 26 (16.1%) | 51 (16.0%) | 12 (12.5%) | 29 (15.6%) | 14 (21.5%) | 22 (16.7%) | |||
| Lymphovascular invasion | |||||||||
| No | 95 (59.0%) | 172 (54.1%) | p = 0.942 | 59 (61.5%) | 104 (55.9%) | p = 0.697 | 36 (55.4%) | 68 (51.5%) | p = 0.554 |
| Yes | 66 (41.0%) | 146 (45.9%) | 37 (38.5%) | 82 (44.1%) | 29 (44.6%) | 64 (48.5%) | |||
| Perineural invasion | |||||||||
| No | 99 (61.5%) | 173 (54.4%) | p = 0.341 | 66 (68.8%) | 104 (55.9%) | p = 0.040 b | 33 (50.8%) | 69 (52.3%) | p = 0.849 |
| Yes | 62 (38.5%) | 145 (45.6%) | 30 (31.2%) | 82 (44.1%) | 32 (49.2%) | 63 (47.7%) | |||
| Cell differentiation | |||||||||
| Well/Moderately | 154 (95.7%) | 289 (90.9%) | p = 0.096 | 91 (94.8%) | 165 (88.7%) | p = 0.129 | 63 (96.9%) | 124 (93.9%) | p = 0.371 |
| Poorly | 7 (4.3%) | 29 (9.1%) | 5 (5.2%) | 21 (11.3%) | 2 (3.1%) | 8 (6.1%) | |||
a AOR (95% CI):1.254 (1.025–1.534); b AOR (95% CI):1.773 (1.027–3.062). The adjusted odds ratios (AORs) with their 95% confidence intervals were estimated by multiple logistic regression models after controlling for stages, tumor T status, lymph node status, metastasis, lymphovascular invasion, perineural invasion, and cell differentiation.